Now Live The BioInsights Podcast Modernizing cell therapy manufacturing to reduce vein-to-vein timesListen now
Learn more about Deterministic Cell Separation™ (DCS) and the Curate® Cell Processing System
Deterministic cell separation revolutionizes cell engineering for advanced therapies.
White paper describing the unique and powerful metabolic and epigenetic advantages of microfluidic DCS as compared to centrifugal processing.VIEW ARTICLE
Centrifugation and Chemical Exposure during CAR-T processing Causes Epigenetic Change - DCS does not.
Presentation from 2023 Meeting on the Mesa highlighting the important and novel finding that centrifugation and chemical exposure during CAR-T processing causes significant metabolic and epigenetic change, a unique perspective available due to the fact microfluidic DCS does not cause these changes.VIEW ARTICLE
Platelets induce regulatory T-cell expansion during CAR-T cell manufacturing.
Poster showing how DCS processing of apheresis vs. Density based approaches both recovers/preserves Naive T cells, while also reducing the number of unwanted regulatory T cells by 50%VIEW ARTICLE
BioInsights - Modernizing cell therapy manufacturing to reduce vein-to-vein times
A Deterministic Cell Separation™ cell preparation that is about 50% less pre-activated, generates about 50% less regulatory T cells (which is critically important to dose quality)...VIEW ARTICLE
Modernizing Cell Therapy Manufacturing with Microfluidics White Paper May 2023
Manufacturing Challenges in Cell and Gene Therapy, Deterministic Cell Separation (TM) (DCS) Microfluidics, CAR T-Cell Manufacturing Process and more...VIEW ARTICLE
Deterministic Cell Separation recovers >2-fold T cells, and more naïve T cells, for autologous cell therapy as compared to centrifugally prepared cells.
DCS technology enables a breakthrough in producing T cell therapies, recovering more total and naive T cells with greater purity. This approach ensures minimal manipulation, significantly streamlined workflows, reduced need for skilled technician time, while simultaneously improving cell recovery and purity of leukocytes for apheresis products.VIEW ARTICLE
Deterministic Lateral Displacement – The next generation of CAR-T cell processing?
Demonstration of 80% cell recovery and 87% platelet depletion from apheresis blood products processed with DLD technology. DLD T-cell preparations showed a high conversion to the T-central memory (Tcm) phenotype and expanded well in culture, resulting in 2-fold greater Tcm compared to Ficoll and direct magnetic approaches. DLD processing provides a path to develop a simple, closed, and automated system for addressing multiple processing steps, human error, contamination, and other technical challenges when manufacturing of therapeutic cells.VIEW ARTICLE
Automated Leukocyte Processing by Microfluidic Deterministic Lateral Displacement
Presents the reduction-to-practice of DLD technology with a commercially produced, high precision plastic microfluidic chip-based device designed for automated and simultaneous washing and size-based separation of human leukocytes, without centrifugation or manual handling of blood samples. The developed protocol averaged 88% WBC recovery, >99% removal, and >99% removal of unbound antibody in ~18 min for 200mL samples.VIEW ARTICLE
Sample Preparation for Flow Cytometry Benefits From Some Lateral Thinking
Review of DLD technology as an improved sample preparation method for flow cytometry, and highlighting how DLD processing can remove both RBCs and excess antibody without the need for lysing agents or centrifugation while eluting the target cells in an appropriate volume for rapid flow cytometry-based analysis.VIEW ARTICLE
Automated Processing of Human Blood Leukocytes by a Plastic Disposable Microfluidic Deterministic Lateral Displacement Device
Demonstration of improved RBC removal and unbiased WBC recovery from human whole blood samples with minimal hands-on time and no adverse affects on cell viability when using reduced-to-practice DLD technology in plastic microchip format.VIEW ARTICLE
DLD Microfluidic Purification and Characterization of Intact and Viable Circulating Tumor Cells in Peripheral Blood
A polymer-based chip-to-chip approach to purify circulating tumor cells. Microfluidic methods using DLD technology provide a uniquely effective and gentle way of processing cells. An example, presented here, being the isolation of CTCs from 1 in a billion blood cells from Breast Cancer Patients.VIEW ARTICLE
Inhibition of clot formation in deterministic lateral displacement arrays for processing large volumes of blood for rare cell capture
Demonstration of optimized DLD (single array) processing for whole blood samples resulting in high yield of harvested PC3 cancer cells. Processing larger blood volumes within one hour is achievable with additional DLD arrays on a single chip.VIEW ARTICLE
Deterministic separation of cancer cells from blood at 10 mL/min
Presents how a microfluidic DLD device can isolate CTCs from blood with capture efficiencies >85% and at flow rate up to 10 mL/min with no impact on cell viability, enabling the option for downstream cell culture and analysis.VIEW ARTICLE
Improved Performance of Deterministic Lateral Displacement Arrays with Triangular Posts
Demonstration of how an optimized DLD array post geometry reduces clogging, lowers hydrostatic pressure requirements, and increases the range of size-based displacement characteristic.VIEW ARTICLE
A microfluidics approach for the isolation of nucleated red blood cells (NRBCs) from the peripheral blood of pregnant women
Report on the development of a high-throughput and highly efficient microfluidic device for isolating rare nucleated red blood cells from maternal blood.VIEW ARTICLE